Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them
Patent Information
- Application Number
- HK42026125494
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-11-06
- Filing Date
- 2026-06-30
- Publication Date
- 2026-09-11
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202511354109.X (22) Application Date 2020.11.01 (30) Priority Data 62 / 931,437 2019.11.06 US (62) Divisional Application Data 202080087155.7 2020.11.01 (71) Applicant Mankind Company Address California, USA (72) Inventors Thomas Hoffman Stephen Ever Kevin Steplerton (74) Patent Agency Beijing Patern Intellectual Property Agency Co., Ltd. 11270 Patent Attorneys Li Xue Yao Kaili (51) Int.Cl. A61K 9 / 72 (2006.01) A61K 31 / 498 (2006.01) A61K 9 / 16(2006.01) A61K 47 / 26(2006.01) A61K 47 / 18(2017.01) A61K 47 / 24(2006.01) A61P 31 / 04(2006.01) A61P 11 / 00(2006.01) A61K 45 / 06(2006.01) A61K 31 / 4709(2006.01) A61K 31 / 546(2006.01) A61K 31 / 606(2006.01) A61K 31 / 4965(2006.01) A61K 31 / 5383(2006.01) A61K 31 / 7048(2006.01) A61K 31 / 7036(2006.01) A61K 31 / 47(2006.01) A61K 31 / 496(2006.01) (54) Invention Title: Compositions of clofazimine, including combinations thereof, methods of preparation thereof, uses thereof, and treatment methods thereof (57) Abstract: This invention relates to pharmaceutical compositions for inhalation and methods of preparation thereof, the pharmaceutical compositions comprising a therapeutically effective dose of clofazimine, wherein the clofazimine is provided in the form of a dry powder. Furthermore, this invention provides pharmaceutical compositions containing clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by this invention can be used to treat and / or prevent pulmonary fungal infections and pulmonary infections caused by mycobacteria and other Gram-positive bacteria.Claims (3 pages), Description (14 pages), CN 121221570 A, 2025.12.30, CN 1 21 22 15 70 A: 1. A pharmaceutical composition for dry powder inhalation, comprising clofazimine or a pharmaceutically acceptable salt or derivative thereof, and a physiologically acceptable and pharmacologically inert excipient, or a mixture of physiologically acceptable and pharmacologically inert excipients, wherein the clofazimine is provided in the form of fine particles with a median aerodynamic diameter of less than 5 μm, and the excipient is provided in the form of coarse particles with a median diameter between 50 μm and 500 μm, wherein the ratio of clofazimine to excipient is about 30:70 w / w. 2. A pharmaceutical composition for dry powder inhalation, comprising clofazimine and a physiologically acceptable, pharmacologically inert solid carrier, said solid carrier comprising a physiologically acceptable, pharmacologically inert excipient, or a mixture of several physiologically acceptable, pharmacologically inert excipients, wherein the clofazimine is provided in the form of fine particles with a median aerodynamic diameter of less than 5 μm, and the excipient is provided in the form of coarse particles with a median diameter between 50 μm and 500 μm, wherein the ratio of clofazimine to excipient is about 30:70 w / w. 3. The pharmaceutical composition of claim 2, wherein the clofazimine is provided in one or more polymorphic forms selected from triclinic FI, monoclinic FII, and orthorhombic FIII, and mixtures of these forms. 4. The pharmaceutical composition of claim 3, wherein the clofazimine is provided substantially in orthorhombic FIII. 5. The composition according to any one of claims 2 to 4, wherein the solid carrier is selected from glucose, arabinose, maltose, sucrose, dextrose, and lactose, and combinations thereof. 6. The composition according to any one of claims 1 to 4, wherein the clofazimine is provided in the form of particles with a median aerodynamic diameter between 1 μm and 3 μm. 7. The composition according to any one of claims 1 to 4, wherein the excipient comprises one phospholipid or a combination of multiple phospholipids. 8. The composition according to any one of claims 1 to 4, wherein the excipient comprises a salt. 9. The composition according to any one of claims 1 to 4, wherein the excipient comprises one amino acid or a combination of multiple amino acids. 10. The composition according to any one of claims 1 to 4, wherein the excipient comprises one sugar or a combination of multiple sugars. 11. A pharmaceutical composition comprising a dry powder inhaler, a dry powder composition according to any one of claims 1 to 10, and a method for introducing the inhalable dry powder composition into a patient's airway by inhalation. 12. The pharmaceutical composition according to claim 11, wherein the dry powder inhaler is a single-dose or multi-dose inhaler.13. The pharmaceutical composition of claim 11, wherein the dry powder inhaler is pre-metered or device-metered. 14. The pharmaceutical composition of any one of claims 1 to 4, for use in treating and / or preventing pulmonary infections caused by mycobacteria or other Gram-positive bacteria. 15. The pharmaceutical composition of any one of claims 11 to 13, for use in treating and / or preventing pulmonary infections caused by mycobacteria or other Gram-positive bacteria. 16. The pharmaceutical composition of claim 14 for the purpose of said infection, wherein the infection is caused by a species of mycobacteria selected from nontuberculous mycobacteria and mycobacterium tuberculosis complexes and combinations thereof. 17. The pharmaceutical composition of claim 15 for the purpose of said infection, wherein the infection is caused by a species of mycobacteria selected from nontuberculous mycobacteria and mycobacterium tuberculosis complexes and combinations thereof. 18. The pharmaceutical composition of claim 16, wherein the nontuberculous mycobacterium is selected from Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessume, and Mycobacterium leprae, and combinations thereof. 19. The pharmaceutical composition of claim 17 for the stated use, wherein the nontuberculous mycobacterium is selected from Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessume, and Mycobacterium leprae, and combinations thereof. 20. The pharmaceutical composition of claim 16 for the stated use, wherein the infection is an opportunistic infection selected from MAC lung disease and nontuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome. 21. The pharmaceutical composition of claim 17 for the stated use, wherein the infection is an opportunistic infection selected from MAC lung disease and nontuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome. 22. The pharmaceutical composition of claim 20, wherein the infection is an opportunistic nontuberculous mycobacterial infection in patients with cystic fibrosis. 23. The pharmaceutical combination of claim 21, wherein the infection is an opportunistic nontuberculous mycobacterial infection in patients with cystic fibrosis.24. A system for providing antibiotic activity in the treatment or prevention of pulmonary infections caused by mycobacteria or other Gram-positive bacteria, wherein the system comprises: 1) a dry powder pharmaceutical formulation comprising: a) a therapeutically effective dose of clofazimine; b) one or more excipients selected from sugars, amino acids, phospholipids, and combinations thereof, wherein the clofazimine is provided in the form of fine particles with a median aerodynamic diameter of less than 5 μm, and the excipients are provided in the form of coarse particles with a median diameter between 50 μm and 500 μm; 2) a container selected from capsules or blister packs of the formulation; and 3) a dry powder inhaler, wherein the clofazimine is present in dry powder form, wherein the ratio of clofazimine to excipients is approximately 30:70 w / w. 25. The pharmaceutical composition according to any one of claims 14, 16, 18, 20, or 22, wherein the composition is administered before, simultaneously with, or after administration of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-aminosalicylate and mixtures thereof. 26. The pharmaceutical composition according to any one of claims 15, 17, 19, 21, or 23, wherein the pharmaceutical composition is administered before, simultaneously with, or after administration of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-aminosalicylate and mixtures thereof. 27. The pharmaceutical composition according to claim 25, wherein the reagent is bedaquiline. 28. The pharmaceutical composition according to claim 26, wherein the reagent is bedaquiline. 29. The pharmaceutical composition of claim 25, wherein the reagent is amikacin. 30. The pharmaceutical composition of claim 26, wherein the reagent is amikacin. 31. Use of the pharmaceutical composition of any one of claims 1 to 10 in the preparation of a medicament for treating or preventing pulmonary infections caused by mycobacteria or other Gram-positive bacteria in patients in need, comprising administering the composition to a patient in need by inhalation. 32. The use of claim 31, wherein the infection is caused by a species of mycobacteria selected from nontuberculous mycobacteria and mycobacterium tuberculosis complexes and combinations thereof. 33. The use of claim 32, wherein the nontuberculous mycobacteria are selected from mycobacteria avianus, mycobacteria intracellularis, mycobacterium abscessis, and mycobacterium leprae, and combinations thereof.34. The use according to claim 31, wherein the infection is an opportunistic infection selected from MAC lung disease and nontuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome. 35. The use according to claim 34, wherein the infection is an opportunistic nontuberculous mycobacterial infection in patients with cystic fibrosis. 36. The use of the pharmaceutical composition according to any one of claims 1 to 10 in the preparation of a medicament for treating or preventing pulmonary infections caused by mycobacteria or other Gram-positive bacteria in patients in need, comprising administering the composition to the patient in need by inhalation before, simultaneously with, or after administration of a reagent selected from bedaquiline or pharmaceutically acceptable salts or derivatives thereof, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-aminosalicylic acid and mixtures thereof. 37. The use according to claim 36, wherein the reagent is bedaquiline or amikacin. 38. The use according to claim 37, wherein the reagent is bedaquiline. Claims 3 / 3 Page 4 CN 121221570 A Compositions of clofazimine, including combinations thereof, methods of preparation thereof, uses thereof, and treatment methods thereof
[0001] This application is a divisional application of patent application No. 202080087155.7, filed November 1, 2020, entitled "Compositions of clofazimine, including combinations thereof, methods of preparation thereof, uses thereof, and treatment methods thereof".
[0002] This invention claims priority to U.S. Provisional Application No. 62 / 931,437, filed November 6, 2019, the contents of which are incorporated herein by reference. Technical Field
[0003] The present invention relates to pharmaceutical compositions for inhalation containing a therapeutically effective dose of clofazimine, wherein the clofazimine is provided in the form of a dry powder; methods of preparation thereof; and uses thereof and treatment methods thereof. Furthermore, the present invention provides pharmaceutical compositions containing clofazimine in the form of an aerosol for pulmonary inhalation.
[0004] The combinations and compositions provided by the present invention can be used to treat and / or prevent pulmonary fungal infections and pulmonary infections caused by mycobacteria and other Gram-positive bacteria. Background Art
[0005] Clofazimine is a highly hydrophobic methylene phenazine antibiotic with anti-mycobacterial and anti-inflammatory activity (Log P = 7.66), and was first described in 1957. Its structural formula is as follows:
[0006]
[0007] The exact mechanism by which clofazimine exerts its antimicrobial effect is not yet clear. However, it is known to preferentially bind to mycobacterial DNA, thereby inhibiting DNA replication and cell growth.Other proposed mechanisms of action include membrane damage / instability, production of membrane-instable lysophospholipids, interference with potassium transport, and / or intracellular redox cycles. Although clofazimine has significant in vitro activity against Mycobacterium tuberculosis (MTB), including multidrug-resistant strains, it was generally considered ineffective in treating pulmonary tuberculosis until recently (see, for example, Cholo M et al., J Antimicrob Chemother, 2012 Feb, 67(2):290-8).
[0008] Clofazimine is one of the three main drugs recommended by the World Health Organization for the treatment of leprosy caused by Mycobacterium leprae, and has been increasingly used in recent years to treat other mycobacterial infections, such as drug-resistant tuberculosis and infections caused by nontuberculous mycobacteria (NTM).
[0009] Clofazimine is almost insoluble in water and exhibits high membrane permeability, and has therefore been classified as a Class II drug in the Biopharmaceutical Classification System (BCS).
[0010] To overcome the problems associated with poor oral absorption and bioavailability of drugs, various strategies, such as micronization, nano-sizing, supercritical fluid recrystallization, spray freeze-drying into liquids, solid dispersions, and solutions, have been employed in optimizing oral dosage forms, as described in page 1 / 14 of the instruction manual (CN 121221570 A).
[0011] As it is classified as a BCS Class II drug, clofazimine is generally considered an ideal candidate for formulation into a solid dispersion to improve oral bioavailability (see, for example, Bhusnure et al. IJRPC 2014, 4(4), 906-918).
[0012] Consistent with this, due to the lipophilic nature of clofazimine, it is typically administered as a microcrystalline suspension in an oil-wax matrix to improve oral absorption. Absorption in the human body varies considerably after oral administration (45-62%). The adverse effects of clofazimine are dose-related and primarily affect the skin, eyes, and gastrointestinal tract. QT prolongation side effects include reddish-brown discoloration of the skin and conjunctiva, which gradually reverses upon discontinuation. These are the result of chronic systemic accumulation.
[0013] Mycobacterium is a genus of actinomycetes, belonging to the family Mycobacteraceae.
[0014] Mycobacteria are characterized by their rod-shaped form and waxy coat.
[0015] Therefore, mycobacteria can be divided into three groups:
[0016] • Mycobacterium tuberculosis complex – the pathogen of tuberculosis
[0017] • Mycobacterium leprae – the pathogen of leprosy
[0018] • Nontuberculous mycobacteria (NTM), encompassing all nontuberculous mycobacteria or other mycobacteria of Mycobacterium leprae, including Mycobacterium abscessus complex (MABSC) and Mycobacterium avium complex (MAC).
[0019] Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis complex bacteria. As one of the oldest documented human infectious pathogens, TB remains a leading cause of death and morbidity worldwide, with an estimated 10.4 million new TB infections and 1.4 million deaths from active TB in 2015 (see, for example, World Health Organization (WHO) Global Tuberculosis Report 2016). In addition to its high prevalence and mortality, the incidence of multidrug-resistant tuberculosis (MDR-TB) is increasingly alarming, with 580,000 patients currently infected with drug-resistant TB in 2015. Comorbidities such as human immunodeficiency virus (HIV) complicate treatment and resulted in 1.2 million TB cases in 2015.
[0020] To treat MDR-TB infections, the WHO recommends a 9- to 12-month regimen of second-line anti-TB drugs. These regimens (such as the 9- to 12-month Bangladesh regimen), when combined with gatifloxacin, ethambutol, pyrazinamide, and clofazimine for the treatment of MDR-TB, resulted in a relapse-free cure in 87.9% of patients (see, for example, Sotgiu, G, et al., “Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings”, International Journal of Infectious Diseases (2017) 56 190-193).
[0021] Other studies on shortening the treatment time for TB have shown no clinical benefit after 2 weeks of oral clofazimine (see, for example, Diacon, A.H., et al., “Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline”, American Journal of Respiratory and Critical Care Medicine (2015), 191(8), 943-953). The lack of activity is attributed to the low bioavailability of the drug, as it is theoretically believed to have a high affinity for circulating serum proteins. Although clofazimine has been empirically proven to be effective in treating MDR-TB and extensively drug-resistant tuberculosis (XDR-TB), its low bioavailability after systemic administration appears to limit its bioactivity in short-term treatment (see, for example, Swanson, RV, et al., “Pharmacokinetics and Pharmacodynamics of Clofazimine in a Mouse Model of Tuberculosis”, Antimicrobial Agents and Chemotherapy (2015), 59, instruction manual 2 / 14 pages 6 CN 121221570 A (6), 3042-3051).
[0022] It is known that, compared with systemic delivery, inhaled antibiotics for the treatment of lung infections result in higher drug concentrations in the lungs and fewer adverse effects (see, for example, Touw, DJ, et al., “Inhalation of antibiotics in cystic fibrosis”, European Respiratory Journal (1995), 8, 1594-1604), which leads to increased biological activity and efficacy (see, for example, Hickey, AJ, “Inhaled drug treatment for tuberculosis: Past progress and future prospects”, Journal of Controlled Release (2016), 240, 127-134).In vivo mouse models have demonstrated that aerosolized administration of clofazimine showed a significant improvement in bacilli clearance in TB infection models compared to oral administration of clofazimine alone for 28 days after the start of treatment (see, for example, Verma, R.K., et al., “Inhaled microparticles containing clofazimine are efficacious in treatment of experimental Tuberculosis in Mice”, Antimicrobial Agents and Chemotherapy (2013), 57(2), 1050-1052). This short-term improvement is likely due to the direct delivery of clofazimine to the site of infection in the lungs, resulting in higher clofazimine concentrations in lung macrophages within tuberculous granulomas.
[0023] Therefore, aerosolized administration of clofazimine in patients with MDR-TB or XDR-TB infection should further improve patient outcomes and may shorten the duration of current treatment regimens.
[0024] The group of nontuberculous mycobacteria (NTMs), formerly known as atypical or ubiquitous mycobacteria, comprises more than 150 species. NTMs are ubiquitous in nature and exhibit extensive diversity. They can be detected in soil, ground, drinking water, and foods such as pasteurized milk or cheese. Generally, NTM diseases are considered to be of low pathogenicity. However, they can cause serious illness in humans, especially in people with compromised immune systems or a history of lung disease. Currently, NTMs are classified according to their growth rate into slow-growing (SGM) and fast-growing (RGM) mycobacteria.
[0025] The slow-growing Mycobacterium avium complex (MAC) includes species such as Mycobacterium avium, Mycobacterium chimaera, and Mycobacterium intracellulare, which are the most important and common pathogenic NTMs.Like *Mycobacterium kansasii*, *Mycobacterium malmoense*, *Mycobacterium xenopi*, *Mycobacterium simiae*, *Mycobacterium abscessae*, *Mycobacterium gordonae*, *Mycobacterium fortuitum*, and *Mycobacterium chelonae*, they primarily cause lung infections. *Mycobacterium marinum* causes skin and soft tissue infections, such as aquarium granuloma.
[0026] Specifically, RGM causes serious, life-threatening chronic lung disease and disseminated, often fatal, infections. Infections are usually caused by contaminated materials and invasive procedures involving catheters, non-sterile surgery, or injections and implantation of foreign bodies. There are also reports of infection risks from contact with shower heads and whirlpool tubs. NTMs commonly result in opportunistic infections in patients with chronic lung diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other immunocompromised individuals.
[0027] In recent years, rapidly growing (RGM) strains of Mycobacterium abscessus, including subspecies such as Mycobacterium abscessus, Mycobacterium abscessus bolletii, and Mycobacterium abscessus massiliense (MABSC), have become important human pathogens and are associated with significantly higher mortality rates than any other RGM disease.
[0028] Mycobacterium abscessus infection is particularly problematic in patients with CF because it can lead to further lung damage and is often untreatable with a failure rate as high as 60-66% (see, for example, Obregon-Henao A et al., Antimicrobial Agents, 3 / 14 pages, CN 121221570 A and Chemotherapy, November 2015, Vol. 59, No. 11, p. 6904-6912; Qvist, T., Pressler, T., and Katzenstein, TL., “Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis”, Respiratory Research (2014), 15(1): pp. 41-47).
[0029] Human NTM infection is more closely associated with the emergence of the human acquired immunodeficiency syndrome epidemic. Mycobacteria from the Mycobacterium avium complex (MAC) have been identified as a major cause of opportunistic infections in patients infected with human immunodeficiency virus (HIV).
[0030] Several species of NTM are known to form biofilms. Biofilms are small colonies of bacteria embedded in the extracellular matrix that provide stability and resistance to human immune mechanisms. In recent years, some species of NTM have been shown to form biofilms that enhance resistance to disinfectants and antimicrobial agents. Biofilm assembly involves several stages, including reversible attachment, irreversible attachment, biofilm formation through bacterial aggregation, tissue and signal transduction, and eventual diffusion. In this process, bacteria form a matrix containing extracellular polymeric substances (EPS) (such as polysaccharides, lipids, and nucleic acids) to form a complex three-dimensional structure (see, for example, Sousa S. et al., International Journal of Mycobacteriology 4 (2015), 36-43). Specifically, mycobacterial EPS differs in nature from other biofilms because mycobacteria do not produce extracellular polysaccharides (see, for example, Zambrano MM, Kolter R. Mycobacterial biofilms: a greasy way to hold it together. Cell. 2005).Mycobacterial biofilms vary by species but may contain mycolic acid, glycopeptides, mycosyl-diacylglycerol, lipooligosaccharides, lipopeptides, and extracellular DNA (review and original study from: Rose SJ, Babrak LM, Bermudez LE (2015) Mycobacterium avium Possesses Extracellular DNA that Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics. PLoS ONE). Assembly within biofilms is known to enhance resistance to antimicrobial agents (see, for example, Faria S. et al., Journal of Pathogens, Vol 2015, Article ID 809014).
[0031] It is suggested that delivery of aerosolized liposomal amikacin / inhaled amikacin solution nebulized by a jet nebulizer is a novel method for treating NTM pulmonary infections (Rose S. et al, 2014, PLoS ONE, Volume 9, Issue 9, e108703, and Olivier K. et al, Ann Am Thorac Soc Vol 11, No 1, pp. 30-35) and the inhalation of dry powder microparticles of anti-TB drugs for pulmonary delivery is suggested (Cholo M et al., J Antimicrob Chemother. 2012 Feb; 67(2): 290-8 and Fourie B. and Nettey O., 2015 Inhalation Magazine, Verma 2013 Antimicrob Agents Chemother).
[0032] Initially, treatment with parenteral aminoglycosides, tigecycline, and other promising oral antibiotics (such as linezolid, diramani, and bedaquiline) was followed by various combinations of inhaled amikacin and surgical intervention in selected cases, showing promising results in the treatment of NTM lung disease (Lu Ryu et al. TubercRespir Dis 2016; 79:74-84). However, the rising incidence and prevalence of NTM infections (especially NTM lung disease), and the limited treatment options, necessitate the development of new dosage forms / pharmaceutical formulations to improve the bioavailability of currently used antibiotics (such as clofazimine). Inhalation can improve efficacy and reduce adverse reactions compared to oral and parenteral treatments.
[0033] The combination of clofazimine and amikacin has shown synergistic effects in in vitro against Mycobacterium abscessus and Mycobacterium avium (see, for example, van Ingen, J., et al., “In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial Disease”, Antimicrobial Agents and Chemotherapy 56(12), 6324-6327(2012)). Furthermore, the synergistic effect of the combination of clofazimine and bedaquiline against Mycobacterium tuberculosis has been demonstrated (see, for example, Cokol, M. et al., “Efficient Measurement and factorization of high-order drug instructions 4 / 14 pages 8 CN 121221570 A interactions in Mycobacterium tuberculosis”, Sciences Advances 2017:3:e170881, October 11, 2017). The synergistic effect of the clofazimine / bedaquiline combination against non-tuberculous Mycobacterium abscessus has also been demonstrated (Ruth, MM et al., “A Bedaquiline / Clofazimine Combination Regimen Might Add Activity to the Treatment of Clinically Relevant Non-Tuberculous Mycobacterium”, Journal of Antimicrobial Chemotherapy (2019), doi.org / 10.1093 / jac / dky526).
[0034] Fungal pathogens have become a leading cause of death in humans. Current assessments indicate that deaths from invasive fungal infections are comparable to those from more well-known infectious diseases such as tuberculosis. Candida albicans, Cryptococus neoformans, and Aspergilliis fumigatus are the most common fungal pathogens in humans. Each of these species causes hundreds of thousands of infections annually, with unacceptably high mortality rates due to poor diagnosis and limited treatment options.Clofazimine has been shown to be effective against a variety of fungi as a combination agent (see, for example, Robbins, N., et al., “An Antifungal Combination Matrix Identifies a Rich Pool of Adjuvant Molecules that Enhance Drug Activity against Diverse Fungal Pathogens”, Cell Reports 13, 1481-1492, November 17, 2015). Fungi also play a role as symbiotics, colonizers and / or pathogens in cystic fibrosis (see, for example, Chotirmall, S.H. and McElvaney, NG, “Fungiin the cystic fibrosis lung: Bystanders or pathogens?”, The International Journal of Biochemistry & Cell Biology 52 (2014), 161-173).
[0035] According to one aspect of the invention, pulmonary mycobacterial infection is treated with clofazimine delivered directly to the lungs via oral inhalation. The dose delivered to the patient is lower than the corresponding oral dose.
[0036] One aspect of the invention is the delivery of 10 to 20 mg of clofazimine to the lungs of a patient. Clofazimine may be in the form of a pure drug or in the form of a pharmaceutically acceptable derivative or salt.
[0037] Many embodiments are available for delivering the amount of drug to a patient via an aerosol. One embodiment is a dry powder inhaler.
[0038] Many embodiments will be conceived by those skilled in the art, which are described with slight variations but still have the same therapeutic effect of delivering 10 to 20 mg of clofazimine to the lungs.
[0039] 1. Alternative forms of clofazimine: The powder may be prepared using pharmaceutically acceptable derivatives, polymorphs, or salts of clofazimine.
[0040] 2. Use of alternative inhalers: The formulation is suitable for any dry powder inhaler, including other capsule-based devices, blister strip inhalers, reservoir inhalers, disposable inhalers, and reusable inhalers.
[0041] 3. Alternative particle size: Each inhaler has different resistance to airflow, and an inhaler with higher resistance results in a lower inhalation flow rate. By selecting an inhaler with higher resistance (lower inhalation flow rate), a larger particle size (up to 10 μm) can be used for effective lung delivery.
[0042] 4. Alternative formulation components: Many grades of lactose can be used in inhaled formulations of different sizes and geometries. Small lactose particles can also be premixed to aid dispersion. Lactose can be replaced with physiologically acceptable, pharmacologically inert solid carriers. Other excipients, such as phospholipids, salts, surfactants, or polymers, can be added to aid aerosol dispersion.
[0043] 5. Alternative formulation forms: Alternatively, clofazimine and excipients can be dissolved in one or more solvents and sprayed dry as a mist.
[0044] The compositions of the present invention provide significantly increased delivery of aerosolized clofazimine to the lower lung (i.e., to the bronchi, bronchioles, and alveoli of the central and lower peripheral lungs) through aerosolization with a suitable inhaler, thereby significantly enhancing therapeutic efficacy.
[0045] Furthermore, the inhalation device should preferably be further adapted for local pulmonary delivery of an aerosol with an optimal particle size distribution for uniform deposition in the lower lung.
[0046] Therefore, the present invention provides an aerosol having aerosol particles of a size that facilitates delivery to the alveoli and bronchioles. A suitable aerodynamic particle size for the alveoli and bronchioles is between 1 and 5 μm. Larger particles selectively deposit in the upper lungs (i.e., bronchi and trachea) and the oral cavity and throat (i.e., the oropharyngeal region). Therefore, the inhalation device is adapted to produce an aerosol with a median mass aerodynamic diameter (MMAD) in the range of about 1 to about 5 μm, and preferably in the range of about 1 to about 3 μm. In another embodiment, the particle size distribution is narrow and the geometric standard deviation (GSD) is less than about 2.5. Detailed Description
[0047] The present invention is based on the unexpected discovery that, through the pulmonary aerosol administration of clofazimine, deeper (i.e., deeper) lung deposition of the active agent can be achieved, thereby significantly increasing the bioavailability of the extremely hydrophobic BCS Class II agent, resulting in a significant increase in therapeutic efficacy and a reduction in systemic side effects.
[0048] In another aspect, this discovery provides improved antibiotic treatment for infections caused by mycobacteria and Gram-positive bacteria, particularly NTM pulmonary infections (such as cystic fibrosis, chronic obstructive pulmonary disease, and opportunistic infections in immunocompromised patients (such as HIV patients).
[0049] Furthermore, the present invention aims to overcome the systemic side effects of established oral treatment regimens for Gram-positive bacterial pulmonary infections, particularly TB and NTM infections of the lungs, and aims to reduce the dosage and duration of treatment with clofazimine.
[0050] Those skilled in the art will understand that this application also discloses each and any combination of the various features disclosed herein.
[0051] Definitions
[0052] The term "pharmaceutically acceptable salt" means a salt that retains the biological efficacy and properties of the compounds of the present invention and is not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid salts and / or base salts due to the presence of amino and / or carboxyl groups or similar groups. Pharmaceutically acceptable acid addition salts can be formed from inorganic and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Organic acids that can be derivatized include, for example, acetic acid, propionic acid, naphthalic acid, oleic acid, palmitic acid, pamoic acid, stearic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, ascorbic acid, glucocorticoid, glucuronic acid, lactic acid, lactobionic acid, tartaric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc.
[0053] Pharmaceutically acceptable base addition salts can be formed from inorganic and organic bases. Inorganic bases that can be derivatized include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, etc.; particularly preferred are ammonium salts, potassium salts, sodium salts, calcium salts, and magnesium salts. Organic bases that can be derived include, for example, primary, secondary, and tertiary amines. Substituted amines include naturally occurring substituted amines, cyclic amines, basic ion exchange resins, etc., particularly such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, histidine, arginine, lysine, benzylamine, N-methylglucosamine, and ethanolamine. Other acids include dodecyl sulfate, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, and saccharin.
[0054] According to the invention, in addition to free bases, salts of methanesulfonic acid, maleic acid, isonicotinic acid, nicotinic acid, malonic acid, and salicylic acid are preferred, particularly chlorofazimine methanesulfonate.
[0055] As used herein, the term "pharmaceuticalally acceptable derivative" refers, for example, to the compounds disclosed in US 9,540,336, the entire disclosure of which is incorporated herein.Furthermore, the term "derivative" refers to that described in Lu, Y., Zhen, M., Wang, B., Fu, L., Zhao, W., Li, P., Xu, J., Zhu, H., Jin, H., Yin, D. Huang, H., Upton, AM. and Ma, Z., “Clofazimine Analogs with Efficacy against experimental Tuberculosis and reduced Potential for Accumulation”, Antimicrobial Agents and Chemotherapy (2011), 55(11):pp.5185-5193. Additionally, the term "pharmaceuticalally acceptable derivative" of a compound is, for example, a prodrug of the compound. Typically, a prodrug is a derivative of a compound that, when administered, provides the active form of the compound. These derivatives may, for example, be esters or amides of carboxyl groups, carboxyl esters of hydroxyl groups, or phosphate esters of hydroxyl groups.
[0056] The term "patient" refers to a mammal, preferably a human, who requires prevention and / or treatment as described herein.
[0057] "Therapeutic effective amount," "therapeutic effective dose," or "pharmaceutically effective amount" means the amount of clofazimine or its pharmaceutically acceptable salts or derivatives that have a therapeutic effect as disclosed in this invention. The dose of clofazimine that can be used for treatment is the therapeutic effective amount. Thus, as used herein, the therapeutic effective amount refers to those amounts of clofazimine that have been determined to produce the desired therapeutic effect based on clinical trial results and / or animal model infection studies.
[0058] The amount and daily dose of clofazimine can be routinely determined by those skilled in the art and will vary depending on several factors, such as the specific microbial strain involved. The amount may also depend on the patient's height, weight, sex, age, and medical history. For prophylactic treatment, the therapeutic effective amount refers to the amount that effectively prevents microbial infection.
[0059] "Therapeutic effect" means the relief of one or more symptoms of infection to a certain extent and includes curing the infection. "Cure" means the elimination of symptoms of an active infection, including the complete or substantial elimination of excess members of the surviving microorganisms involved in the infection, at or below the detection threshold conventionally measured. However, even after a cure, the infection may have some long-term or permanent effects (such as extensive tissue damage). As used herein, “treatment effect” is defined as a statistically significant reduction in bacterial load in the host, the emergence of drug resistance, or improvement in symptoms of infection as measured by human clinical outcomes or animal studies.
[0060] As used herein, the terms “treat”, “treatment”, “treating” refer to the administration of a pharmaceutical composition / combination for preventive and / or therapeutic purposes.
[0061] The terms “preventive treatment” or “prevention” refer to treating a patient who is not yet infected but is susceptible to a specific infection or has a specific risk of infection. The term “therapeutic treatment” refers to administering treatment to a patient who already has an infection. Therefore, in a preferred embodiment, treatment is (for therapeutic or preventative purposes) administering a therapeutically effective amount of clofazimine to a mammal.
[0062] Unless otherwise stated herein, the term “inhalation” means inhalation into the lungs.
[0063] Unless otherwise stated herein, the term “infection” as used herein refers to a lung infection.
[0064] Unless otherwise stated, the term “substantially” when used to refer to the purity of a compound means a purity of 95% or higher of the compound.
[0065] Unless otherwise stated, the term “appropriate particle size” refers to the particle size of clofazimine in the composition, or in a composition that provides the desired therapeutic effect when administered to a patient.
[0066] Unless otherwise stated, the term “appropriate concentration” refers to the concentration of a component in a composition or combination that provides a pharmaceutically acceptable composition or combination.
[0067] Pharmaceutical Compositions and Combinations
[0068] Clofazimine has been shown to exist in at least four polymorphic forms (see, for example, Bannigan, et al., specification 7 / 14, page 11, CN 121221570 A “Investigation into the Solid and Solution Properties of Known and Novel Polymorphs of the Antimicrobial Molecule Clofazimine”, Cryst. Growth Des. 2016, 16(12), pp. 7240-7250). Clofazimine can exist in triclinic form FI, monoclinic form FII, and orthorhombic form FIII. Another polymorph, FIV, is only observed at high temperatures.
[0069] Therefore, in a further embodiment of the invention, a pharmaceutical composition is provided comprising:
[0070] (a) a therapeutically effective dose of clofazimine;
[0071] wherein the clofazimine is provided in the form of granules in a dry powder, and
[0072] wherein the median particle size of the clofazimine is less than 5 μm and the D90 is less than 6 μm, preferably less than 2 μm and the D90 is less than 3 μm, and wherein the clofazimine is provided in one or more polymorphic forms selected from triclinic form FI, monoclinic form FII, and orthorhombic form FIII, and mixtures of these forms. In a preferred embodiment, the clofazimine is provided substantially in orthorhombic form FIII.
[0073] In another embodiment, a pharmaceutical composition according to any of the composition embodiments described herein is provided for use in combination with an agent for dispersing and / or disrupting biofilms, with a mucolytic agent and / or a mucolytic agent, and / or an agent for reducing biofilm formation, wherein the agent for dispersing and / or disrupting biofilms, the mucolytic agent and / or the mucolytic agent and / or the agent for reducing biofilm formation is selected from: periodate, sodium dodecyl sulfate, sodium bicarbonate, tromethamine, silver nanoparticles, bismuth thiols, ethylenediaminetetraacetic acid, phosphatidylcholine-modified gold nanoparticles loaded with gentamicin, chelating agents, cis-2-decenoic acid, D-amino acids, D-enantiomer peptides, gallium porphyrin IX, gallium protoporphyrin IX, curcumin, patulin, penicillic acid, baicalein, naringenin, ursolic acid, asiatic acid, corosolic acid, fatty acids, host defense peptides, and antimicrobial peptides. In another embodiment, the composition for this purpose is applied before, simultaneously with or after the administration of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin and para-aminosalicylate and mixtures thereof.
[0074] In another embodiment, a pharmaceutical combination according to any of the combined embodiments described herein is provided for use in conjunction with an agent for dispersing and / or disrupting biofilms, with a mucolytic agent and / or a mucolytic agent, and / or an agent for reducing biofilm formation, wherein the agent for dispersing and / or disrupting biofilms, the mucolytic agent and / or the mucolytic agent and / or the agent for reducing biofilm formation is selected from: periodate, sodium dodecyl sulfate, sodium bicarbonate, tromethamine, silver nanoparticles, bismuth thiol, ethylenediaminetetraacetic acid, phosphatidylcholine-modified gold nanoparticles loaded with gentamicin, chelating agents, cis-2-decenoic acid, D-amino acids, D-enantiomer peptides, gallium porphyrin IX, gallium protoporphyrin IX, curcumin, patulin, penicillic acid, baicalin, naringenin, ursolic acid, asiatic acid, corosolic acid, fatty acids, host defense peptides, and antimicrobial peptides. In another embodiment, the combination for the stated purpose is used to administer the composition of the invention before, simultaneously with, or after the administration of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-aminosalicylate and mixtures thereof. In another embodiment, the composition is administered before, simultaneously with, or after the administration of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, and acaricin, and mixtures thereof. In a further embodiment, the composition is administered before, simultaneously with, or after the administration of bedaquiline or its pharmaceutically acceptable salts or derivatives.
[0075] In another embodiment, a pharmaceutical composition according to any of the composition embodiments described herein is provided for treating and / or preventing lung infections caused by mycobacteria or other Gram-positive bacteria. In a further embodiment, the infection is caused by a mycobacterial species selected from nontuberculous mycobacteria and mycobacterium tuberculosis complexes and combinations thereof. In a further embodiment, the nontuberculous mycobacteria are selected from Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessum, and Mycobacterium leprae, and combinations thereof. In another embodiment, the infection is an opportunistic infection selected from MAC lung disease and nontuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome. In another embodiment, the infection is an opportunistic nontuberculous mycobacterial infection in patients with cystic fibrosis. In another embodiment, the composition for the stated purpose is administered before, simultaneously with, or after the administration of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-aminosalicylate and mixtures thereof. In another embodiment, the composition is administered before, simultaneously with, or after the administration of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, and acaricin, and mixtures thereof. In a further embodiment, the composition is administered before, simultaneously with, or after the administration of bedaquiline or its pharmaceutically acceptable salts or derivatives.
[0076] In another embodiment, a pharmaceutical combination according to any of the combined embodiments described herein is provided for the treatment and / or prevention of pulmonary infections caused by mycobacteria or other Gram-positive bacteria. In a further embodiment, the infection is caused by a species of mycobacteria selected from nontuberculous mycobacteria and mycobacterium tuberculosis complexes and combinations thereof. In a further embodiment, the nontuberculous mycobacteria are selected from Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessum, and Mycobacterium leprae, and combinations thereof. In another embodiment, the infection is an opportunistic infection selected from MAC lung disease and nontuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome. In another embodiment, the infection is an opportunistic nontuberculous mycobacterial infection in patients with cystic fibrosis. In another embodiment, the combination for the stated purpose is used to administer the composition of the invention before, simultaneously with, or after administration of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-aminosalicylic acid, and mixtures thereof.In another embodiment, the combination for the stated purpose is used to administer the composition of the invention before, simultaneously with or after the administration of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, and acaricin, and mixtures thereof. In another embodiment, the combination for the stated purpose is used to administer the composition of the invention before, simultaneously with or after the administration of bedaquiline or its pharmaceutically acceptable salts or derivatives.
[0077] In another embodiment, a system is provided for providing antibiotic activity in the treatment or prevention of lung infections caused by mycobacteria or other Gram-positive bacteria, wherein the system comprises:
[0078] 1) an aerosolized drug combination comprising:
[0079] (a) a therapeutically effective dose of clofazimine; and
[0080] 2) a dry powder inhaler,
[0081] wherein the clofazimine is provided in the form of dry powder,
[0082] and wherein the median mass aerodynamic diameter of the aerosol particles produced by the system is 1 to 5 μm.
[0083] In a further embodiment, a pharmaceutical composition according to any of the composition embodiments described herein is provided for treating and / or preventing pulmonary fungal infections or Clostridium difficile or combinations thereof. In another embodiment, a pharmaceutical composition according to any of the composition embodiments described herein is provided for treating and / or preventing pulmonary fungal infections. In a further embodiment, the pulmonary fungal infection is Candida albicans or Aspergillus fumigatus or combinations thereof.
[0084] In a further embodiment, a pharmaceutical composition according to any of the combination embodiments described herein is provided for treating and / or preventing pulmonary fungal infections or Clostridium difficile or combinations thereof. A pharmaceutical composition according to any of the combination embodiments described herein is provided for treating and / or preventing pulmonary fungal infections. In a further embodiment, the pulmonary fungal infection is Candida albicans or Aspergillus fumigatus or combinations thereof.
[0085] In another embodiment, a method of treating or preventing pulmonary infections in a patient in need is provided, comprising administering a composition according to any of the composition embodiments described herein by inhalation. In another embodiment, the infection, as described on page 9 / 14 of the specification (CN 121221570 A), is caused by a species of mycobacterium selected from nontuberculous mycobacteria and mycobacterium tuberculosis complexes and combinations thereof. In another embodiment, the nontuberculous mycobacteria are selected from Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessum, and Mycobacterium leprae, and combinations thereof. In a further embodiment, the infection is an opportunistic infection selected from MAC lung disease and nontuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome. In another embodiment, the infection is an opportunistic nontuberculous mycobacterial infection in patients with cystic fibrosis.
[0086] In a further embodiment, a method is provided for treating or preventing lung infections caused by mycobacteria or other Gram-positive bacteria in patients in need, comprising administering, by inhalation, a composition according to any of the compositions described herein, before, simultaneously with, or after administration of a pharmaceutically acceptable salt selected from bedaquiline or its derivatives, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-aminosalicylate and mixtures thereof. In another embodiment, the agent is bedaquiline or amikacin. In a further embodiment, the agent is bedaquiline.
[0087] Particle Size and Distribution
[0088] The therapeutic effect of aerosol therapy depends on the dose deposited and its distribution. Aerosol particle size is one of the important variables defining the dose deposited in the lungs and the distribution of the drug aerosol.
[0089] Typically, inhaled aerosol particles are deposited through one of two mechanisms: impaction (usually dominant for larger aerosol particles) and sedimentation (dominantly dominant for smaller aerosol particles). Impaction occurs when the momentum of inhaled aerosol particles is large enough that they do not follow the airflow and encounter physiological surfaces. In contrast, when extremely small aerosol particles carried by the inhaled airflow encounter physiological surfaces due to gravity, sedimentation mainly occurs in the lower lungs.
[0090] Lung drug delivery can be achieved by inhaling aerosols through the mouth and throat. Aerosol particles with an aerodynamic diameter greater than about 5 μm typically do not reach the lungs; instead, they tend to impact the back of the throat and be swallowed and may be absorbed orally. Aerosol particles with a diameter of about 3 to about 5 μm are small enough to reach the upper to middle lung regions (conduction airways), but too large to reach the alveoli. Even smaller aerosol particles, about 0.5 to about 3 μm, are able to reach the alveolar regions. Aerosol particles with a diameter less than about 0.5 μm tend to be exhaled during tidal breathing, but can also be deposited in the alveolar regions by breath-holding.
[0091] Aerosols used in pulmonary drug delivery consist of aerosol particles of various sizes, and therefore statistical descriptive terms are used. Aerosols used in pulmonary drug delivery are typically described by their median mass diameter (MMD), i.e., half the mass is contained in aerosol particles larger than the MMD, and half the mass is contained in aerosol particles smaller than the MMD. For particles with uniform density, the median volume diameter (VMD) can be used interchangeably with MMD. VMD and MMD are determined by laser diffraction. The width of the distribution is described by the geometrical standard deviation (GSD). However, the aerodynamic diameter of the particles more accurately describes the deposition of aerosol particles in the respiratory tract, and therefore, the median mass aerodynamic diameter is typically used. MMAD is determined by inertial impaction or time-of-flight measurement.
[0092] Nevertheless, for purposes of description, aerosol particle size will be given in MMAD units, measured at room temperature using a next-generation impactor (NGI), in accordance with U.S. Pharmacopeia practice. Disclosed in Process Revision <601> Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers, Pharmacopeial Forum (2003), Volume Number 29, pages 1176-1210, also disclosed in Jolyon Mitchell, Mark Nagel, “Particle Size Analysis of Aerosols from Medicinal Inhalers”, KONA Powder and Particle Journal (2004), Volume 22, pages 32-65.
[0093] According to the present invention, the particle size of the aerosol is optimized to maximize the deposition of clofazimine at the site of infection and to maximize tolerance. The aerosol particle size can be expressed as the mass median aerodynamic diameter (MMAD). Large particles (e.g., MMAD > 5 μm) tend to deposit in the extrathoracic airway and upper airway because they are too large to pass through the bends in the airway. Intolerance (e.g., cough and bronchospasm) may be caused by large particle deposition in the upper airway.
[0094] Therefore, according to a preferred embodiment, the MMAD of the aerosol should be less than about 5 μm, preferably between about 1 and 5 μm, and more preferably less than 3 μm (<3 μm).
[0095] However, guided breathing strategies may be employed to allow larger particles to pass through the extrathoracic airways and upper airways and enter the lungs more deeply than during tidal breathing, which will increase the deposition of the aerosol in the middle and lower lungs. Guided breathing strategies may be as slow as 100 ml / min. Therefore, when used with a guided breathing strategy, the preferred MMAD of the aerosol should be less than about 10 μm.
[0096] For Treatment and / or Prevention
[0097] The pharmaceutical compositions and combinations of pharmaceuticals (aerosols, aerosolized formulations) and systems according to the invention are intended for the treatment and / or prevention of lung infections caused by mycobacteria or other clofazimine-sensitive bacteria, such as Staphylococcus aureus (including methicillin-resistant and vancomycin-resistant intermediate strains), Streptococcus pneumoniae, and Enterococcus spp.The pharmaceutical compositions and combinations of the present invention can also be used to treat and / or prevent pulmonary fungal infections.
[0098] Dosing of clofazimine
[0099] In the case of Mycobacterium abscessus infection, the daily lung dose (i.e., the dose deposited in the lungs) of clofazimine administered according to the present invention is about 10-20 mg.
[0100] The daily lung dose will be divided accordingly based on the frequency of administration (once or twice daily).
[0101] According to the present invention, clofazimine is administered once or twice daily, such that the total daily lung dose is about 10 to 20 mg.
[0102] It will be apparent to those skilled in the art that the above amounts relate to the free base of clofazimine, and the dosages of derivatives and salts must be adjusted accordingly based on the MIC of the respective compound and the strain.
[0103] Accordingly, in a first aspect of the invention, a pharmaceutical composition for dry powder inhalation is provided, the composition comprising clofazimine or a pharmaceutically acceptable salt or derivative thereof of suitable particle size, and a physiologically acceptable pharmacologically inert excipient of suitable particle size, or a mixture of multiple physiologically acceptable pharmacologically inert excipients of suitable particle size.
[0104] In a second aspect, a pharmaceutical composition for dry powder inhalation is provided, comprising clofazimine of suitable particle size and a physiologically acceptable pharmacologically inert solid carrier, said solid carrier comprising a physiologically acceptable pharmacologically inert excipient of suitable particle size, or a mixture of multiple physiologically acceptable pharmacologically inert excipients of suitable particle size.
[0105] In a third aspect, a pharmaceutical composition according to the second aspect is provided, wherein clofazimine is provided in one or more polymorphic forms selected from triclinic FI, monoclinic FII, and orthorhombic FIII, and mixtures of these polymorphs.
[0106] In a fourth aspect of the invention, a pharmaceutical composition according to the third aspect is provided, wherein clofazimine is provided substantially in orthorhombic form FIII.
[0107] In a fifth aspect, a pharmaceutical composition according to any one of the first to fourth aspects is provided, wherein the solid carrier is selected from glucose, arabinose, maltose, sucrose, dextrose, and lactose, and combinations thereof.
[0108] In a sixth aspect, a pharmaceutical composition according to any one of the first to fifth aspects is provided, wherein the solid carrier is provided in the form of coarse particles with a median mass diameter between 50 and 500 μm.
[0109] In a seventh aspect, a composition according to any one of the first to sixth aspects is provided, wherein clofazimine is provided in the form of fine particles with a median mass aerodynamic diameter of less than 5 μm.
[0110] In an eighth aspect, a composition according to the seventh aspect is provided, wherein chlorfazimine is provided in the form of fine particles with a median aerodynamic diameter between 1 μm and 3 μm.
[0111] In a ninth aspect, a composition according to any one of the first to fourth aspects is provided, wherein the particles have a homogeneous composition, and the particles simultaneously comprise chlorfazimine and one or more excipients.
[0112] In a tenth aspect, a composition according to the ninth aspect is provided, wherein the median aerodynamic diameter of the particles is less than 5 μm.
[0113] In an eleventh aspect, a composition according to any one of the ninth or tenth aspects is provided, wherein the median aerodynamic diameter of the particles is between 1 μm and 3 μm.
[0114] In a twelfth aspect, a composition according to any one of the first to eleventh aspects is provided, wherein the excipient comprises one phospholipid or a combination of multiple phospholipids.
[0115] In a thirteenth aspect, a composition according to any one of the first to eleventh aspects is provided, wherein the excipient comprises a salt.
[0116] In a fourteenth aspect, a composition according to any one of the first to eleventh aspects is provided, wherein the excipient comprises one or a combination of amino acids.
[0117] In a fifteenth aspect, a composition according to any one of the first to eleventh aspects is provided, wherein the excipient comprises one or a combination of sugars.
[0118] In a sixteenth aspect, a pharmaceutical composition is provided, comprising a dry powder inhaler, a dry powder composition according to any one of the first to fifteenth aspects, and a means of delivering the inhalable dry powder composition into a patient's airway by inhalation.
[0119] In a seventeenth aspect, a pharmaceutical composition according to the sixteenth aspect is provided, wherein the dry powder inhaler is a single-dose or multi-dose inhaler.
[0120] In an eighteenth aspect, a pharmaceutical composition according to the sixteenth aspect is provided, wherein the dry powder inhaler is pre-dose or device-dose.
[0121] In a nineteenth aspect, a pharmaceutical composition according to any one of the first to fifteenth aspects is provided for use in treating and / or preventing lung infections caused by mycobacteria or other Gram-positive bacteria.
[0122] In a twentieth aspect, a pharmaceutical composition according to any one of the sixteenth to eighteenth aspects is provided for use in treating and / or preventing pulmonary infections caused by mycobacteria or other Gram-positive bacteria.
[0123] In a twenty-first aspect, a pharmaceutical composition according to the nineteenth aspect is provided for the use therein, wherein the infection is caused by a species of mycobacteria selected from nontuberculous mycobacteria and mycobacterium tuberculosis complexes and combinations thereof.
[0124] In a twenty-second aspect, a pharmaceutical composition according to the twenty-first aspect is provided for the use described herein, wherein the infection is caused by a mycobacterial species selected from nontuberculous mycobacteria and mycobacterial complexes and combinations thereof.
[0125] In a twenty-third aspect, a pharmaceutical composition according to the twenty-first aspect is provided, wherein the nontuberculous mycobacteria are selected from Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessume, and Mycobacterium leprae, and combinations thereof.
[0126] In a twenty-fourth aspect, a pharmaceutical composition according to the twenty-second aspect is provided for the use described herein, wherein the nontuberculous mycobacteria are selected from Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessume, and Mycobacterium leprae, and combinations thereof.
[0127] In a twenty-fifth aspect, a pharmaceutical composition according to the twenty-first aspect is provided for the use described herein, wherein the infection is an opportunistic infection selected from MAC lung disease and nontuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome.
[0128] In a twenty-sixth aspect, a pharmaceutical composition according to the twenty-second aspect is provided for the said use, wherein the infection is an opportunistic infection selected from MAC lung disease and nontuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome.
[0129] In a twenty-seventh aspect, a pharmaceutical composition according to the twenty-fifth aspect is provided, wherein the infection is an opportunistic nontuberculous mycobacterial infection in patients with cystic fibrosis.
[0130] In a twenty-eighth aspect, a pharmaceutical composition according to the twenty-sixth aspect is provided, wherein the infection is an opportunistic nontuberculous mycobacterial infection in patients with cystic fibrosis.
[0131] In a twenty-ninth aspect, a system for providing antibiotic activity in the treatment or prevention of pulmonary infections caused by mycobacteria or other Gram-positive bacteria, wherein the system comprises:
[0132] 1) a dry powder pharmaceutical preparation comprising
[0133] a) a therapeutically effective dose of clofazimine,
[0134] b) one or more excipients selected from sugars, amino acids, phospholipids and combinations thereof,
[0135] 2) a container selected from capsules or blister packages, and
[0136] 3) a dry powder inhaler,
[0137] wherein clofazimine is present in dry powder form, and wherein the median mass diameter of the particles containing clofazimine is 1 to 5 μm.
[0138] In a thirtieth aspect, a pharmaceutical composition according to any one of the nineteenth, twenty-first, twenty-third, twenty-fifth, or twenty-seventh aspects is provided, wherein the composition is administered before, simultaneously with, or after the application of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-aminosalicylate and mixtures thereof.
[0139] In a thirty-first aspect, a pharmaceutical combination according to any one of the twentieth, twenty-second, twenty-fourth, twenty-fifth, or twenty-eighth aspects is provided, wherein the pharmaceutical combination is administered before, simultaneously with, or after the application of a reagent selected from bedaquiline or its pharmaceutically acceptable salts or derivatives, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-aminosalicylate and mixtures thereof.
[0140] In a thirty-second aspect, a pharmaceutical composition according to the thirtieth aspect is provided, wherein the reagent is bedaquiline.
[0141] In the thirty-third aspect, a pharmaceutical composition according to the thirty-first aspect is provided, wherein the reagent is bedaquiline.
[0142] In the thirty-fourth aspect, a pharmaceutical composition according to the thirtieth aspect is provided, wherein the reagent is amikacin.
[0143] In the thirty-fifth aspect, a pharmaceutical composition according to the thirtieth aspect is provided, wherein the reagent is amikacin.
[0144] In the thirty-sixth aspect, a method for treating or preventing pulmonary infections caused by mycobacteria or other Gram-positive bacteria in a patient in need is provided, comprising administering a composition according to any one of the first to fifteenth aspects by inhalation.
[0145] In the thirty-seventh aspect, a method for treating or preventing according to the thirty-sixth aspect is provided, wherein the infection is caused by a species of mycobacteria selected from nontuberculous mycobacteria and mycobacterium tuberculosis complexes and combinations thereof.
[0146] In the thirty-eighth aspect, a method for treating or preventing according to the thirty-seventh aspect is provided, wherein the nontuberculous mycobacteria are selected from mycobacterium avium, mycobacterium intracellulare, mycobacterium abscessume, and mycobacterium leprae, and combinations thereof.
[0147] In the thirty-ninth aspect, a treatment or prevention method according to the thirty-sixth aspect is provided, wherein the infection is an opportunistic infection selected from nontuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease, or acquired immunodeficiency syndrome.
[0148] In the fortieth aspect, a treatment or prevention method according to the thirty-ninth aspect is provided, wherein the infection is an opportunistic nontuberculous mycobacterial infection in patients with cystic fibrosis.
[0149] In a forty-first aspect, a method is provided for treating or preventing pulmonary infections caused by mycobacteria or other Gram-positive bacteria in patients in need, comprising administering, by inhalation, a composition according to any one of the first to fifteenth aspects, before, simultaneously with, or after administration of a reagent selected from bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefoxitin, amikacin, clarithromycin, pyrazinamide, rifampin, moxifloxacin, levofloxacin, and para-aminosalicylate and mixtures thereof.
[0150] In a forty-second aspect, a method of treatment or prevention according to the forty-first aspect is provided, wherein the reagent is bedaquiline or amikacin.
[0151] In a forty-third aspect, a method of treatment or prevention according to the forty-second aspect is provided, wherein the reagent is bedaquiline.
[0152] Example 1: Aerosol DPI
[0153] One embodiment of the invention uses an aerosol DPI, an inhaler that stores a drug in a capsule. Clofazimine is micronized into particles with an MMD of less than 2 μm using an air jet mill, and then mixed with larger lactose particles (MMD greater than 50 μm) to form a formulation. This formulation contains approximately 30% clofazimine by weight. Approximately 250 mg of the formulation (75 mg clofazimine) is filled into capsules. 13% to 28% of the dose is deposited in the lungs; therefore, this embodiment delivers 9.75 mg to 21 mg of clofazimine to the lungs.DESCRIPTION 14 / 14 Page 18 CN 121221570 A ABSTRACT The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine, wherein the clofazimine is provided in the form of dry powder, and processes for the preparation thereof. Furthermore, the present invention provides pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention can be used for the treatment and / or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, as well as pulmonary fungal infections.
Claims
1. A pharmaceutical composition for dry powder inhalation comprising clofazimine or a pharmaceutically acceptable salt or derivative thereof, and a physiologically acceptable, pharmacologically inert excipient, or a mixture of a plurality of physiologically acceptable, pharmacologically inert excipients, wherein, The clofazimine is provided in the form of fine particles having a mass median aerodynamic diameter of less than 5 μm and the excipient is provided in the form of coarse particles having a mass median diameter between 50 μm and 500 μm, wherein the ratio of clofazimine to excipient is about 30:70 w / w.
2. A pharmaceutical composition for dry powder inhalation comprising clofazimine and a physiologically acceptable, pharmacologically inert, solid carrier, said solid carrier comprising a physiologically acceptable, pharmacologically inert, excipient, or a mixture of a plurality of physiologically acceptable, pharmacologically inert, excipients, wherein, The clofazimine is provided in the form of fine particles having a mass median aerodynamic diameter of less than 5 μm and the excipient is provided in the form of coarse particles having a mass median diameter between 50 μm and 500 μm, wherein the ratio of clofazimine to excipient is about 30:70 w / w.
3. The pharmaceutical composition of claim 2, wherein, The clofazimine is provided in one or more polymorphic forms selected from the group consisting of triclinic form FI, monoclinic form FII and orthorhombic form FIII and mixtures thereof.
4. The pharmaceutical composition of claim 3, wherein, The clofazimine is provided substantially in the orthorhombic form FIII.
5. The composition according to any one of claims 2 to 4, wherein, The solid carrier is selected from the group consisting of glucose, arabinose, maltose, sucrose, dextrose and lactose and combinations thereof.
6. The composition according to any one of claims 1 to 4, wherein, The clofazimine is provided in the form of particles having a mass median aerodynamic diameter between 1 μm and 3 μm.
7. The composition according to any one of claims 1 to 4, wherein, The excipient comprises a phospholipid or a combination of phospholipids.
8. The composition according to any one of claims 1 to 4, wherein, The excipient comprises a salt.
9. The composition according to any one of claims 1 to 4, wherein, The excipient comprises an amino acid or a combination of amino acids.
10. The composition according to any one of claims 1 to 4, wherein, The excipient comprises a sugar or a combination of sugars.
11. A pharmaceutical combination comprising a dry powder inhalation device, a dry powder composition according to any one of claims 1 to 10, and a means for introducing the inhalable dry powder composition into the airways of a patient by inhalation.
12. The pharmaceutical combination of claim 11, wherein, The dry powder inhalation device is a single dose or a multi-dose inhaler.
13. The pharmaceutical combination of claim 11, wherein, The dry powder inhalation device is pre-metered or device metered.
14. The pharmaceutical composition according to any one of claims 1 to 4 for use in the treatment and / or prevention of pulmonary infections caused by mycobacteria or other gram-positive bacteria.
15. The pharmaceutical combination according to any one of claims 11 to 13 for use in the treatment and / or prevention of pulmonary infections caused by mycobacteria or other gram-positive bacteria.
16. The pharmaceutical composition for use according to claim 14, wherein, The infection is caused by a Mycobacterium species selected from the group consisting of non-tuberculous mycobacteria and the Mycobacterium tuberculosis complex and combinations thereof.
17. The pharmaceutical combination for the use of claim 15, wherein, The infection is caused by a Mycobacterium species selected from the group consisting of non-tuberculous mycobacteria and the Mycobacterium tuberculosis complex and combinations thereof.
18. The pharmaceutical composition of claim 16, wherein, The non-tuberculous mycobacteria are selected from the group consisting of M. avium, M. intracellulare, M. abscessus and M. leprae and combinations thereof.
19. The pharmaceutical combination for the use of claim 17, wherein, The non-tuberculous mycobacteria are selected from the group consisting of M. avium, M. intracellulare, M. abscessus and M. leprae and combinations thereof.
20. The pharmaceutical composition for use according to claim 16, wherein, The infection is an opportunistic infection selected from the group consisting of MAC lung disease and non-tuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease or acquired immune deficiency syndrome.
21. The pharmaceutical combination for the use of claim 17, wherein, The infection is an opportunistic infection selected from the group consisting of MAC lung disease and non-tuberculous infections in patients with cystic fibrosis, chronic obstructive pulmonary disease or acquired immune deficiency syndrome.
22. The pharmaceutical composition of claim 20, wherein, The infection is an opportunistic non-tuberculous mycobacterial infection in a patient with cystic fibrosis.
23. The pharmaceutical combination of claim 21, wherein, The infection is an opportunistic non-tuberculous mycobacterial infection in a patient with cystic fibrosis.
24. A system for providing antibiotic activity in the treatment or provision of prophylaxis of pulmonary infections caused by mycobacteria or other gram-positive bacteria, wherein, The system comprises: 1) a dry powder pharmaceutical formulation comprising: a) a therapeutically effective dose of clofazimine, b) one or more excipients selected from the group consisting of sugars, amino acids, phospholipids and combinations thereof, wherein the clofazimine is provided in the form of fine particles having a mass median aerodynamic diameter of less than 5 pm, and the excipient is provided in the form of coarse particles having a mass median diameter between 50 pm and 500 pm, 2) a container selected from the group consisting of a capsule or a blister pack, and 3) a dry powder inhaler, wherein the clofazimine is present in the form of a dry powder, wherein the ratio of clofazimine to excipient is about 30:70 w / w.
25. The pharmaceutical composition of any one of claims 14, 16, 18, 20, or 22, wherein, The composition is for administration prior to, simultaneously with or following administration of an agent selected from the group consisting of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefixime, amikacin, clarithromycin, pyrazinamide, rifampicin, moxifloxacin, levofloxacin and para-aminosalicylate and mixtures thereof.
26. The pharmaceutical combination of claim 15, 17, 19, 21, or 23, wherein, The pharmaceutical combination is for administration prior to, simultaneously with or following administration of an agent selected from the group consisting of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefixime, amikacin, clarithromycin, pyrazinamide, rifampicin, moxifloxacin, levofloxacin and para-aminosalicylate and mixtures thereof.
27. The pharmaceutical composition of claim 25, wherein, The agent is bedaquiline.
28. The pharmaceutical combination of claim 26, wherein, The agent is bedaquiline.
29. The pharmaceutical composition of claim 25, wherein, The agent is amikacin.
30. The pharmaceutical combination of claim 26, wherein, The agent is amikacin.
31. Use of a pharmaceutical composition according to any one of claims 1 to 10 for the manufacture of a medicament for the treatment or prevention of a pulmonary infection caused by a mycobacterium or other gram-positive bacteria in a patient in need thereof, comprising administering the composition by inhalation to a patient in need thereof.
32. The use of claim 31, wherein, The infection is caused by a mycobacterium species selected from the group consisting of non-tuberculous mycobacteria and the Mycobacterium tuberculosis complex and combinations thereof.
33. The use of claim 32, wherein, The non-tuberculous mycobacteria are selected from the group consisting of M. avium, M. intracellulare, M. abscessus and M. leprae and combinations thereof.
34. The use of claim 31, wherein, The infection is an opportunistic infection selected from the group consisting of MAC pulmonary disease and non-tuberculous infections in a patient with cystic fibrosis, chronic obstructive pulmonary disease or acquired immunodeficiency syndrome.
35. The use of claim 34, wherein, The infection is an opportunistic non-tuberculous mycobacterial infection in a patient with cystic fibrosis.
36. Use of a pharmaceutical composition according to any one of claims 1 to 10 for the manufacture of a medicament for the treatment or prevention of a pulmonary infection caused by a mycobacterium or other gram-positive bacteria in a patient in need thereof, comprising administering the composition by inhalation to a patient in need thereof prior to, simultaneously with or following administration of an agent selected from the group consisting of bedaquiline or a pharmaceutically acceptable salt or derivative thereof, cefixime, amikacin, clarithromycin, pyrazinamide, rifampicin, moxifloxacin, levofloxacin and para-aminosalicylate and mixtures thereof.
37. The use of claim 36, wherein, The agent is bedaquiline or amikacin.
38. The use of claim 37, wherein, The agent is bedaquiline. The agent is bedaquiline.
